

Jia Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3741546/publications.pdf>

Version: 2024-02-01

171
papers

6,966
citations

61977

43
h-index

76898

74
g-index

176
all docs

176
docs citations

176
times ranked

9307
citing authors

#	ARTICLE	IF	CITATIONS
1	The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. <i>Pharmacological Research</i> , 2022, 175, 105998.	7.1	21
2	Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2388-2408.	6.4	24
3	Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. <i>Pathogens</i> , 2022, 11, 293.	2.8	16
4	Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis. <i>Frontiers in Molecular Medicine</i> , 2022, 2, .	1.9	6
5	Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2022, 234, 114229.	5.5	1
6	Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, , .	6.4	1
7	BRD4&MK2 signaling: target for Crohn&TM's Disease&associated fibrosis. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
8	Discovery of Balanced and Novel G Protein Biased Agonists for the Orphan Receptor GPR52. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
9	Inhibition of BET Family Proteins Suppresses African Swine Fever Virus Infection. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	6
10	Allosteric inhibitors of the main protease of SARS-CoV-2. <i>Antiviral Research</i> , 2022, 205, 105381.	4.1	23
11	Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. <i>Genes and Diseases</i> , 2021, 8, 448-462.	3.4	54
12	Molecular targeting therapies for neuroblastoma: Progress and challenges. <i>Medicinal Research Reviews</i> , 2021, 41, 961-1021.	10.5	150
13	Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. <i>Cancer Letters</i> , 2021, 496, 16-29.	7.2	60
14	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. <i>Medicinal Research Reviews</i> , 2021, 41, 1375-1426.	10.5	28
15	Emerging roles of SIRT6 in human diseases and its modulators. <i>Medicinal Research Reviews</i> , 2021, 41, 1089-1137.	10.5	75
16	Small-molecule inhibitors for the Prp8 intein as antifungal agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	15
17	Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. <i>Theranostics</i> , 2021, 11, 6873-6890.	10.0	21
18	Subanesthetic ketamine with an AMPAkinine attenuates motor impulsivity in rats. <i>Behavioural Pharmacology</i> , 2021, 32, 335-344.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Discovery of a Small Molecule Inhibitor of Human Adenovirus Capable of Preventing Escape from the Endosome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1617.	4.1	4
20	Discovery of RSV-Induced BRD4 Protein Interactions Using Native Immunoprecipitation and Parallel Accumulation-Serial Fragmentation (PASEF) Mass Spectrometry. <i>Viruses</i> , 2021, 13, 454.	3.3	20
21	Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4257-4288.	6.4	23
22	Oleamide Analogues as Positive Allosteric Modulators of the Serotonin (5-HT _{2C}) and 5-HT _{2A} Receptors. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
23	Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 217, 113381.	5.5	7
24	Bromodomain-Containing Protein 4 (BRD4) Inhibitors as Emerging Therapeutics for Opioid Use Disorder. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
25	Structure Activity Relationships of Novel GPR52 Agonists that Suppress Psychostimulant Behavior. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
26	HJC0416 Attenuates Fibrogenesis in Activated Hepatic Stellate Cells via STAT3 and NF- κ B Pathways. <i>Journal of Surgical Research</i> , 2021, 261, 334-342.	1.6	1
27	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. <i>Nature Communications</i> , 2021, 12, 2877.	12.8	35
28	Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer. <i>Cell Death and Differentiation</i> , 2021, 28, 2931-2945.	11.2	24
29	Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 39, 116157.	3.0	6
30	Development of Allosteric Modulators of Voltage-Gated Na ⁺ Channels: A Novel Approach for an Old Target. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 841-848.	2.1	5
31	Broad Impact of Exchange Protein Directly Activated by cAMP 2 (EPAC2) on Respiratory Viral Infections. <i>Viruses</i> , 2021, 13, 1179.	3.3	2
32	Efficacy of Novel Aminoxyacetic Acid Prodrugs in Colon Cancer Models: Towards Clinical Translation of the Cystathionine β -Synthase Inhibition Concept. <i>Biomolecules</i> , 2021, 11, 1073.	4.0	14
33	Further lead optimization on Bax activators: Design, synthesis and pharmacological evaluation of 2-fluoro-fluorene derivatives for the treatment of breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2021, 219, 113427.	5.5	7
34	Differential Modulation of the Voltage-Gated Na ⁺ Channel 1.6 by Peptides Derived From Fibroblast Growth Factor 14. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 742903.	3.5	10
35	Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, .	2.1	4
36	Exchange Protein Directly Activated by cAMP 2 Enhances Respiratory Syncytial Virus-Induced Pulmonary Disease in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 757758.	4.8	3

#	ARTICLE	IF	CITATIONS
37	Intracellular receptor EPAC regulates von Willebrand factor secretion from endothelial cells in a PI3K/eNOS-dependent manner during inflammation. <i>Journal of Biological Chemistry</i> , 2021, 297, 101315.	3.4	5
38	Bromodomain Containing Protein 4 (BRD4) Regulates Expression of its Interacting Coactivators in the Innate Response to Respiratory Syncytial Virus. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 728661.	3.5	12
39	In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus. <i>Acta Pharmaceutica Sinica B</i> , 2021, , .	12.0	10
40	Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, S38-S62.	1.9	14
41	Pharmacologically Targeting the Fibroblast Growth Factor 14 Interaction Site on the Voltage-Gated Na ⁺ Channel 1.6 Enables Isoform-Selective Modulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13541.	4.1	4
42	Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. <i>Drug Discovery Today</i> , 2020, 25, 126-132.	6.4	39
43	Design, Synthesis, and Pharmacological Evaluation of Analogues Derived from the PLEV Tetrapeptide as Protein-Protein Interaction Modulators of Voltage-Gated Sodium Channel 1.6. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11522-11547.	6.4	8
44	A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression. <i>Frontiers in Pharmacology</i> , 2020, 11, 1043.	3.5	24
45	6 NOVEL BRD4 INHIBITORS BLOCK THE PATHOLOGICAL ACTIVATION OF BRD4-NF- κ B SIGNALING AND SUPPRESS COLONIC INFLAMMATION IN IBD MOUSE MODELS. <i>Inflammatory Bowel Diseases</i> , 2020, 26, S7-S7.	1.9	1
46	Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13951-13972.	6.4	10
47	Bidirectional Modulation of the Voltage-Gated Sodium (Nav1.6) Channel by Rationally Designed Peptidomimetics. <i>Molecules</i> , 2020, 25, 3365.	3.8	8
48	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15187-15217.	6.4	49
49	Discovery of Novel Substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12830-12852.	6.4	13
50	JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both <i>In Vitro</i> and <i>In Vivo</i> . <i>ACS Infectious Diseases</i> , 2020, 6, 2616-2628.	3.8	32
51	STING controls intestinal homeostasis through promoting antimicrobial peptide expression in epithelial cells. <i>FASEB Journal</i> , 2020, 34, 15417-15430.	0.5	16
52	Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. <i>Nature Communications</i> , 2020, 11, 4457.	12.8	480
53	Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. <i>Cancers</i> , 2020, 12, 3651.	3.7	6
54	Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580. <i>Journal of Virology</i> , 2020, 94, .	3.4	20

#	ARTICLE	IF	CITATIONS
55	Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT _{2C} Receptor-Positive Allosteric Modulators with Enhanced Drug-like Properties. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7529-7544.	6.4	14
56	Discovery of phenanthridine analogues as novel chemical probes disrupting the binding of DNA to γ FosB homodimers and γ FosB/JunD heterodimers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127300.	2.2	5
57	Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3142-3160.	6.4	21
58	Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. <i>ACS Infectious Diseases</i> , 2020, 6, 909-915.	3.8	252
59	HJC0152 suppresses human non-small cell lung cancer by inhibiting STAT3 and modulating metabolism. <i>Cell Proliferation</i> , 2020, 53, e12777.	5.3	24
60	Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127162.	2.2	8
61	Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5242-5256.	6.4	53
62	Synthesis and Biochemical Evaluation of Noncyclic Nucleotide Exchange Proteins Directly Activated by cAMP 1 (EPAC1) Regulators. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5159-5184.	6.4	12
63	Mechanism of Action of an EPAC1-Selective Competitive Partial Agonist. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4762-4775.	6.4	15
64	Mapping of the FGF14:Nav1.6 complex interface reveals FLPK as a functionally active peptide modulating excitability. <i>Physiological Reports</i> , 2020, 8, e14505.	1.7	8
65	Targeting Transcription Checkpoint Using a Novel CDK9 Inhibitor in Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
66	Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 88-127.	6.4	109
67	Design, Synthesis, and Biological Evaluation of Substituted 4,6-Dihydrospiro[[1,2,3]triazolo[4,5- <i>b</i>]pyridine-7,3- <i>a</i> -indoline]-2,5-dione Analogues as Potent NS4B Inhibitors for the Treatment of Dengue Virus Infection. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7941-7960.	6.4	26
68	Applications of Bioorthogonal Chemistry in Tumor-Targeted Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 892-897.	2.1	8
69	Positive-allosteric modulation of the 5-HT _{2C} receptor: implications for neuropsychopharmacology and neurotherapeutics. <i>Neuropsychopharmacology</i> , 2019, 44, 230-231.	5.4	12
70	GPCR Drug Discovery: Emerging Targets, Novel Approaches and Future Trends. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1363-1364.	2.1	9
71	Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 589-605.	5.5	12
72	Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling. <i>Journal of Proteomics</i> , 2019, 205, 103415.	2.4	24

#	ARTICLE	IF	CITATIONS
73	Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing). <i>Tuberculosis</i> , 2019, 116, S28-S33.	1.9	27
74	Discovery of niclosamide and its O-alkylamino-tethered derivatives as potent antibacterial agents against carbapenemase-producing and/or colistin resistant Enterobacteriaceae isolates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1399-1402.	2.2	22
75	Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 792-799.	2.8	15
76	Exchange protein directly activated by cAMP plays a critical role in regulation of vascular fibrinolysis. <i>Life Sciences</i> , 2019, 221, 1-12.	4.3	19
77	Methylglyoxal and a spinal TRPA1-AC1-Epac cascade facilitate pain in the db/db mouse model of type 2 diabetes. <i>Neurobiology of Disease</i> , 2019, 127, 76-86.	4.4	29
78	An NPY Y1 receptor antagonist unmasks latent sensitization and reveals the contribution of protein kinase A and Epac to chronic inflammatory pain. <i>Pain</i> , 2019, 160, 1754-1765.	4.2	30
79	Efficacy of Novel Highly Specific Bromodomain-Containing Protein 4 Inhibitors in Innate Inflammation-Driven Airway Remodeling. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 68-83.	2.9	45
80	Identification of peptidomimetics as novel chemical probes modulating fibroblast growth factor 14 (FGF14) and voltage-gated sodium channel 1.6 (Nav1.6) protein-protein interactions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 413-419.	2.2	8
81	Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target. <i>ACS Chemical Neuroscience</i> , 2019, 10, 190-200.	3.5	23
82	Mucosal bromodomain-containing protein 4 mediates aeroallergen-induced inflammation and remodeling. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1380-1394.e9.	2.9	49
83	GPCR Allosteric Modulators: Mechanistic Advantages and Therapeutic Applications. <i>Current Topics in Medicinal Chemistry</i> , 2019, 18, 2002-2006.	2.1	15
84	Effect of N-(2-aminoethyl) ethanolamine on hypertrophic scarring changes in vitro: Finding novel anti-fibrotic therapies. <i>Toxicology and Applied Pharmacology</i> , 2019, 362, 9-19.	2.8	3
85	Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT _{2C} Receptor. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 288-305.	6.4	28
86	Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. <i>Journal of Clinical Investigation</i> , 2019, 129, 3361-3373.	8.2	54
87	Targeting the 5-HT _{2C} Receptor in Biological Context and the Current State of 5-HT _{2C} Receptor Ligand Development. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1381-1398.	2.1	40
88	Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2114-2127.	2.1	4
89	Inhibitory Effects of Novel Oridonin Analog CYD0617 on Hepatic Stellate Cell Activation through NF- κ B and Stat3 Pathways. <i>FASEB Journal</i> , 2019, 33, .	0.5	0
90	Design, Synthesis, In Vitro , and In Silico Evaluation of a Novel Series of Serotonin 5-HT _{2C} Receptor (5-HT _{2C} R) Positive Allosteric Modulators (PAMs). <i>FASEB Journal</i> , 2019, 33, 667.10.	0.5	0

#	ARTICLE	IF	CITATIONS
91	A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma. <i>American Journal of Cancer Research</i> , 2019, 9, 699-713.	1.4	7
92	Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 450-461.	5.5	57
93	Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 354-367.	5.5	16
94	Functional Modulation of Voltage-Gated Sodium Channels by a FGF14-Based Peptidomimetic. <i>ACS Chemical Neuroscience</i> , 2018, 9, 976-987.	3.5	24
95	Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease. <i>Antiviral Research</i> , 2018, 150, 217-225.	4.1	61
96	Synthesis and structure-activity relationship studies of MI-2 analogues as MALT1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3321-3344.	3.0	13
97	AMPA receptor positive allosteric modulators attenuate morphine tolerance and dependence. <i>Neuropharmacology</i> , 2018, 137, 50-58.	4.1	11
98	Selective Antagonists of the Bronchiolar Epithelial NF- κ B-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation. <i>Cell Reports</i> , 2018, 23, 1138-1151.	6.4	38
99	Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis. <i>Cancer Letters</i> , 2018, 424, 97-108.	7.2	30
100	Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2737-2752.	6.4	32
101	Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells. <i>Neuro-Oncology</i> , 2018, 20, 203-214.	1.2	22
102	Natural Compound Oridonin Inhibits Endotoxin-Induced Inflammatory Response of Activated Hepatic Stellate Cells. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	18
103	Proteolysis Targeting Chimera (PROTAC): A Paradigm-Shifting Approach in Small Molecule Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2018, 18, 1354-1356.	2.1	47
104	Exchange Protein Directly Activated by cAMP Modulates Ebola Virus Uptake into Vascular Endothelial Cells. <i>Viruses</i> , 2018, 10, 563.	3.3	18
105	Exchange Proteins Directly Activated by cAMP and Their Roles in Respiratory Syncytial Virus Infection. <i>Journal of Virology</i> , 2018, 92, .	3.4	14
106	Luteolin-Mediated Inhibition of Hepatic Stellate Cell Activation via Suppression of the STAT3 Pathway. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1567.	4.1	21
107	Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection. <i>Molecules</i> , 2018, 23, 474.	3.8	85
108	Antifibrosis Effect of Novel Oridonin Analog CYD0618 Via Suppression of the NF- κ B Pathway. <i>Journal of Surgical Research</i> , 2018, 232, 283-292.	1.6	14

#	ARTICLE	IF	CITATIONS
109	Apoptosis Regulator BAX. , 2018, , 356-360.		0
110	Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/ β -catenin Axis with HJC0152. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 578-590.	4.1	45
111	Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1633-1639.	2.2	41
112	Drug Discovery Targeting Bromodomain-Containing Protein 4. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4533-4558.	6.4	244
113	Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo- N -phenylacetohydrazonoyl cyanide analogues as potent EPAC antagonists. <i>European Journal of Medicinal Chemistry</i> , 2017, 134, 62-71.	5.5	8
114	Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs. <i>Cell Death and Disease</i> , 2017, 8, e2701-e2701.	6.3	23
115	Modulation of Bax and mTOR for Cancer Therapeutics. <i>Cancer Research</i> , 2017, 77, 3001-3012.	0.9	24
116	Structure-activity relationships of 2-substituted phenyl- N -phenyl-2-oxoacetohydrazonoyl cyanides as novel antagonists of exchange proteins directly activated by cAMP (EPACs). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5163-5166.	2.2	9
117	Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. <i>Cell Research</i> , 2017, 27, 1046-1064.	12.0	153
118	YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway. <i>Theranostics</i> , 2017, 7, 2339-2349.	10.0	23
119	Hydrogen Sulfide Contributes to Retinal Neovascularization in Ischemia-Induced Retinopathy. , 2016, 57, 3002.		17
120	Cystathionine- β -Synthase Inhibition for Colon Cancer: Enhancement of the Efficacy of Aminooxyacetic Acid via the Prodrug Approach. <i>Molecular Medicine</i> , 2016, 22, 361-379.	4.4	59
121	Targeting XBP1-mediated β -catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. <i>Oncotarget</i> , 2016, 7, 56842-56854.	1.8	24
122	A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. <i>Cancer Letters</i> , 2016, 380, 393-402.	7.2	53
123	Therapeutic Potential of Spirooxindoles as Antiviral Agents. <i>ACS Infectious Diseases</i> , 2016, 2, 382-392.	3.8	350
124	Functionalized <i>N,N</i> -Diphenylamines as Potent and Selective EPAC2 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 460-464.	2.8	17
125	STAT3 inhibition suppresses hepatic stellate cell fibrogenesis: HJC0123, a potential therapeutic agent for liver fibrosis. <i>RSC Advances</i> , 2016, 6, 100652-100663.	3.6	28
126	Discovery and development of natural product oridonin-inspired anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 102-117.	5.5	132

#	ARTICLE	IF	CITATIONS
127	Direct Activation of Bax Protein for Cancer Therapy. <i>Medicinal Research Reviews</i> , 2016, 36, 313-341.	10.5	160
128	Suppression of Cocaine-Evoked Hyperactivity by Self-Adjuvanting and Multivalent Peptide Nanofiber Vaccines. <i>ACS Chemical Neuroscience</i> , 2016, 7, 546-552.	3.5	50
129	BH4 domain of Bcl-2 as a novel target for cancer therapy. <i>Drug Discovery Today</i> , 2016, 21, 989-996.	6.4	51
130	Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2016, 16, 2107-2114.	2.1	21
131	Apoptosis Regulator BAX. , 2016, , 1-6.		0
132	P-selectin-mediated platelet adhesion promotes tumor growth. <i>Oncotarget</i> , 2015, 6, 6584-6596.	1.8	64
133	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 852-863.	16.8	108
134	Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells. <i>Molecular and Cellular Biochemistry</i> , 2015, 410, 293-300.	3.1	21
135	Evolution in medicinal chemistry of ursolic acid derivatives as anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 648-655.	5.5	116
136	Apigenin inhibits pancreatic stellate cell activity in pancreatitis. <i>Journal of Surgical Research</i> , 2015, 196, 8-16.	1.6	35
137	Biochemical and Pharmacological Characterizations of ESI-09 Based EPAC Inhibitors: Defining the ESI-09 "Therapeutic Window". <i>Scientific Reports</i> , 2015, 5, 9344.	3.3	90
138	Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-1-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6033-6047.	6.4	38
139	Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis. <i>Journal of Surgical Research</i> , 2015, 199, 441-449.	1.6	26
140	Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. <i>Drug Discovery Today</i> , 2015, 20, 105-113.	6.4	99
141	Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy. <i>Current Topics in Medicinal Chemistry</i> , 2015, 15, 699-713.	2.1	63
142	Suppressive Effects of Novel Oridonin Derivative CYD0625 on Activated Hepatic Stellate Cells. <i>FASEB Journal</i> , 2015, 29, 611.5.	0.5	0
143	Biochemical and Pharmacological Characterizations of ESI-09 based EPAC inhibitors. <i>FASEB Journal</i> , 2015, 29, 1022.4.	0.5	0
144	Targeting The Laminin Receptor / PEDF Interface to Treat Prostate Cancer Cells. <i>FASEB Journal</i> , 2015, 29, LB473.	0.5	0

#	ARTICLE	IF	CITATIONS
145	STAT3 Modulation to Enhance Motor Neuron Differentiation in Human Neural Stem Cells. PLoS ONE, 2014, 9, e100405.	2.5	25
146	Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. Oncotarget, 2014, 5, 9966-9979.	1.8	46
147	Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers, 2014, 6, 926-957.	3.7	234
148	Design, synthesis, and characterization of novel apigenin analogues that suppress pancreatic stellate cell proliferation in vitro and associated pancreatic fibrosis in vivo. Bioorganic and Medicinal Chemistry, 2014, 22, 3393-3404.	3.0	33
149	Development of a concise synthetic approach to access oroxin A. RSC Advances, 2014, 4, 45151-45154.	3.6	7
150	Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies. Cancer Letters, 2014, 354, 5-11.	7.2	102
151	Small-molecule Bax agonists for cancer therapy. Nature Communications, 2014, 5, 4935.	12.8	110
152	ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids. Organic and Biomolecular Chemistry, 2014, 12, 8442-8452.	2.8	41
153	Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1). Journal of Medicinal Chemistry, 2014, 57, 6930-6948.	6.4	195
154	Recent Advances in the Discovery of Small Molecules Targeting Exchange Proteins Directly Activated by cAMP (EPAC). Journal of Medicinal Chemistry, 2014, 57, 3651-3665.	6.4	46
155	Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. Journal of Surgical Research, 2014, 190, 55-63.	1.6	57
156	Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). European Journal of Medicinal Chemistry, 2014, 82, 195-203.	5.5	52
157	Allosteric Modulation of G Protein-Coupled Receptors: An Emerging Approach of Drug Discovery. Austin Journal of Pharmacology and Therapeutics, 2014, 2, .	0.0	7
158	KRAS - An Evolving Cancer Target. Austin Journal of Cancer and Clinical Research, 2014, 1, .	0.0	2
159	Overcoming Synthetic Challenges of Oridonin A-Ring Structural Diversification: Regio- and Stereoselective Installation of Azides and 1,2,3-Triazoles at the C-1, C-2, or C-3 Position. Organic Letters, 2013, 15, 3718-3721.	4.6	55
160	Efficient synthesis of ESI-09, a novel non-cyclic nucleotide EPAC antagonist. Tetrahedron Letters, 2013, 54, 1546-1549.	1.4	33
161	A Novel EPAC-Specific Inhibitor Suppresses Pancreatic Cancer Cell Migration and Invasion. Molecular Pharmacology, 2013, 83, 122-128.	2.3	179
162	Discovery of <i>N</i> -Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. ACS Medicinal Chemistry Letters, 2013, 4, 180-185.	2.8	108

#	ARTICLE	IF	CITATIONS
163	A Combined Bioinformatics and Chemoinformatics Approach for Developing Asymmetric Bivalent AMPA Receptor Positive Allosteric Modulators as Neuroprotective Agents. <i>ChemMedChem</i> , 2013, 8, 226-230.	3.2	24
164	Fragment-based drug design and identification of HJC0123 , a novel orally bioavailable STAT3 inhibitor for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 498-507.	5.5	91
165	Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5048-5058.	6.4	97
166	Identification and Characterization of Small Molecules as Potent and Specific EPAC2 Antagonists. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 952-962.	6.4	59
167	Oridonin Ring A-Based Diverse Constructions of Enone Functionality: Identification of Novel Dienone Analogues Effective for Highly Aggressive Breast Cancer by Inducing Apoptosis. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8814-8825.	6.4	64
168	Exploration of Synthetic Approaches and Pharmacological Evaluation of PNU-69176E and Its Stereoisomer as 5-HT _{2C} Receptor Allosteric Modulators. <i>ACS Chemical Neuroscience</i> , 2012, 3, 538-545.	3.5	29
169	5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4038-4043.	2.2	52
170	The Novel Triple Reuptake Inhibitor JZAD-IV-22 Exhibits an Antidepressant Pharmacological Profile without Locomotor Stimulant or Sensitization Properties. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 762-770.	2.5	25
171	Piperidine-Based Cocaine/Modafinil Hybrid Ligands as Highly Potent Monoamine Transporter Inhibitors: An Efficient Drug Discovery by Rational Lead Hybridization. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5821-5824.	6.4	28